Elsamitrucin

DB05129InvestigationalSmall molecule

The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873).

Mechanism: Elsamitrucin induces single strand breaks in DNA and inhibits topoisomerase I and II, enzymes that play an important role in DNA replication.
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (non-hodgkin's).Curator reviewed
Formula / weight: C₃₃H₃₅NO₁₃ · 653.6299 g/mol (avg)
Code names: BBM-2478A · BMY-28090

Resolves to

Compound

UNIIZTV0FOB6NUCAS97068-30-9ChEMBLCHEMBL2106409PubChem5362259

Structure

InChIKeyMGQRRMONVLMKJL-KWJIQSIXSA-NSMILES

CO[C@@H]1[C@@H](N)[C@@H](O[C@H]2[C@H](OC3=CC=CC4=C3C3=C5C(C(=O)OC6=C5C(=C(C)C=C6)C(=O)O3)=C4O)O[C@H](C)[C@H](O)[C@]2(C)O)O[C@H](C)[C@@H]1O

Targets

Q02880TOP2BP11388TOP2AP11387TOP1

What you can answer from here — as of January 29, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elsamitrucin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account